Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.
The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.
Read Full Release
Migraine and cataract therapies and a transit solution for vaccines such as Covid-19 are among the new cutting-edge innovations to be presented in the virtual 30th MedTech Investing Europe Conference on 21-22 October, 2020.
Campden Wealth organisers said attendees will be able to participate online and benefit from everything the MedTech Investing events normally offered—industry leading content, speakers from some of the world’s foremost investors and dedicated networking for both investors and presenting companies. Attendees were required to pre-register and will receive full details, access links and schedule in advance of the event.
Read Full Release
Three tech startups from various parts of the Garden State competed in a Startup Showdown last week that focused on real-world data and evidence collection.
The Startup Showdowns are presented by TechUnited:NJ (New Brunswick) and Tech Council Ventures (Summit) and hosted by Jasmine Hoffman.
Pitching were Daniel Ferrara, founder and CEO of Roseland-based WellCare Today; Luke Malanga, COO of Cedar Knolls-based DataBiologics; and Kirsten Hund Blair, cofounder and CEO of Princeton-based Lambent Data.
The investors who gave feedback were: Mark Kolb, entrepreneur in residence, Tech Council Ventures, who focuses on the healthcare industry; Steven Cohen, partner, Morgan Lewis (Philadelphia), who is chair of the Morgan Lewis emerging business and technology practice and an angel investor; and Ren Roome, principal, Boston Millennia Partners.
The complete video of the program can be found here.
For this episode, Lambent Data took home the audience choice award.
Read Full Release
The Evolving Relationship Between Real World Data and Clinical Trials with Nancy Dreyer and C.K. Wang
In this episode of Real World Talk, host Zoe Li talks to Nancy Dreyer, Chief Scientific Officer of IQVIA, and COTA’s own Chief Medical Officer, Dr. C.K. Wang.
They discuss the interactions between real world data and clinical trials, and how the two approaches can complement each other. They also look at why the Lancet retracted a large study into the use of hydroxychloroquine to treat COVID-19 in June, after questions were raised about its curation and application of real world data.
Read Full Release
Working in and around revenue cycle technology for so long, we often communicate about features and benefits in shorthand. With so many different types of health information solutions, ownership models, service lines and so forth, sometimes we talk about things in an unknown, or jargon-y language without even realizing it.
Take charge reconciliation as an example. At medaptus this means the act of confirming that for every visit and/or service delivered, a charge exists. When it doesn’t, this is evident and actionable. Charge reconciliation is vital to all of our products.
Read Full Release
IBM (NYSE: IBM) Watson Health and OrbitalRX® today announced a strategic collaboration that aims to help address the emerging drug shortage crisis. The companies are combining OrbitalRX's Drug Shortage Management Platform and IBM® Micromedex® into one unified solution called "OrbitalRX and Micromedex," designed to create a single source for healthcare providers and pharmacy teams to access evidence-based treatment information alongside a hospital's current drug inventory status and drug sourcing options. This one solution aims to quickly analyze the supply chain and identify clinical alternatives for drugs that are in short supply.
Read Full Release
Healthcare access and inequity challenges have been exacerbated by the COVID-19 pandemic; members of at-risk populations around the world are increasingly delaying important specialist care. Today Digital Diagnostics Inc., a pioneering global healthcare autonomous artificial intelligence (AI) company formerly known as IDx, announces it has acquired 3Derm Systems, Inc. of Boston, MA. This acquisition makes Digital Diagnostics the global leader in healthcare autonomous AI, where it is the sole holder of autonomous AI healthcare systems that are De Novo authorized by the U.S. Food & Drug Administration (FDA), enabling the company to close more care gaps widened by COVID-19.
Read Full Release
For 20 years medaptus has applied information technology to solve problems that are common and costly to healthcare organizations. To mark its twentieth anniversary, the company recently provided an update on its extensive technology capabilities grounded in interoperability.
Read Full Release
Ernst & Young LLP (EY US) has announced that David Weingard, CEO and Founder of Cecelia Health, was named an Entrepreneur Of The Year® 2020 New York Award finalist. Now in its 34th year, the Entrepreneur Of The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. David was selected as one of the finalists by a panel of independent judges comprising former winners and business leaders from multiple industries.
Read Full Release
Healthcare access and inequity challenges have been exacerbated by the COVID-19 pandemic; members of at-risk populations around the world are increasingly delaying important specialist care. Today Digital Diagnostics Inc., a pioneering global healthcare autonomous artificial intelligence (AI) company formerly known as IDx, announces it has acquired 3Derm Systems, Inc. of Boston, MA. This acquisition makes Digital Diagnostics the global leader in healthcare autonomous AI, where it is the sole holder of autonomous AI healthcare systems that are De Novo authorized by the U.S. Food & Drug Administration (FDA), enabling the company to close more care gaps widened by COVID-19.
Read Full Release
